Novartis seeks early approval for heat-failure drug

03/31/2014 | Reuters

Novartis has halted clinical trials of its new heart-failure drug LCZ696 to seek early regulatory approval after results showing that patients on the drug lived longer, without hospitalization, than those given the current standard-care medication, enalapril. "If full results are robust, LCZ696 could represent another blockbuster drug in the category of cardiovascular medicine that the company knows well," said Bernstein analyst Tim Anderson. Novartis plans to release data from its clinical trials at an upcoming conference.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN